Christopher R. Loose - Jul 4, 2023 Form 4/A - Amendment Insider Report for Frequency Therapeutics, Inc. (FREQ)

Role: Chief Scientific Officer
Signature: /s/ James P. Abely, Attorney-in-Fact for Christopher R. Loose
Stock symbol: FREQ
Transactions as of: Jul 4, 2023
Transactions value $: -$471
Form type: 4/A - Amendment
Date filed: 7/12/2023, 09:15 PM
Date Of Original Report: Jul 7, 2023
Previous filing: Jan 27, 2023
Next filing: Jul 7, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FREQ	Common Stock	Options Exercise		+150K	+299.7%		200K	Jul 4, 2023	Direct	F1
transaction	FREQ	Common Stock	Sale	-$471	-1.38K	-0.69%	$0.34	199K	Jul 6, 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FREQ	Restricted Stock Unit	Options Exercise		-150K	-100%		0	Jul 4, 2023	Common Stock	150K		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock.
F2	Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person.
F3	This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.33 to $0.35. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F4	The Restricted Stock Units fully vested on July 4, 2023 and do not have an expiration date.

Remarks:

This Form 4/A is being filed to correct (i) the vesting transaction dates, (ii) the number of Restricted Stock Units reported as vesting on Table II in columns 5 and 7, (iii) the aggregate derivatives following the transaction on Table II in column 9, (iv) the acquisition of shares on Table I in column 4, and (v) the aggregate securities following the transaction in column 5 of Table I.